Nasdaq

Teva Canada Announces Availability of Aermony RespiClick™, an Innovative New Device for the Treatment of Bronchial Asthma

Asthma is a chronic, lifelong condition without a cure that can cause life-threatening symptoms and affects 3.8 million Canadians.1–3 Although inhaled medication is the cornerstone of therapy, ...
Becker's Hospital Review

Teva earns FDA approval for 2 new asthma inhaler drugs

Both products deliver dry powder asthma medication through Teva’s RespiClick inhaler. The AirDuo RespiClick contains the same active ingredients as GlaxoSmithKline’s inhaler drug Advair, while the ...
Nasdaq

Teva Canada Says Aermony RespiClick To Treat Bronchial Asthma Available In Three Dose Options

(RTTNews) - Teva Canada, a unit of Teva Pharmaceutical Industries Ltd. (TEVA), announced Monday the product availability of Aermony RespiClick, a new device for the treatment of bronchial asthma. The ...
Seeking Alpha

Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured Patients

PARSIPPANY, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced today the launch of a new patient access ...
Business Wire

Teva Canada Announces Availability of Aermony RespiClick™, an Innovative New Device for the Treatment of Bronchial Asthma

Aermony RespiClick™ (fluticasone propionate inhalation powder), available in three dose options Asthma is a chronic, lifelong condition without a cure that can cause life-threatening symptoms and ...